Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

NCT ID: NCT02298985

Last Updated: 2019-01-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2017-05-31

Brief Summary

Schizophrenia is still remained one of the disabling disorders despite progress in treatment of mental disturbances. Ten to thirty percents of patients have a little or no benefit from treatment with all kinds of antipsychotics using adequate dosages and duration. Treatment of these patients has remained a persistent public health problem since medication-resistant patients are often highly symptomatic. Curcumin is one of the main curcuminoids isolated from this perennial herb. It possesses a variety of pharmacological activities, including anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects and crosses the blood-brain barrier. The purpose of our suggested study is to examine the efficacy of curcumin as add-on the conventional antipsychotic psychopharmacotherapy in chronic schizophrenia patients.

Detailed Description

Study Design This is a 24-week, randomized, double-blind, placebo-controlled investigation of 40 chronic schizophrenia patients.

Participants Forty patients will be drawn from the patient population of Be'er Sheva Mental Health Center. Recruitment period will last over 2 years.

Patients will be required to have a primary diagnosis of chronic schizophrenia as defined in DSM-IV with predominantly persistent negative signs.

The study will commence only after approval by the local Institutional Ethics Review Board ("Helsinki Committee"). Only willing subjects and able to provide written informed consent, after receiving a comprehensive explanation of the study procedures, will be included in the study. Confidentially will be ensured by means of a number coding system, and all completed research forms will be stored in secure areas.

Procedure Patients will continue receiving their regular antipsychotic medication. The dose will be kept constant for at least 3 months prior to entry and throughout the study period. Curcumin is provided as Curcumin Forte ® (Solgar Israel SupHerb). Circumin capsules are supplied as an 1000 mg soft gelatin capsule for three daily oral administration with meals. At entry patients will receive curcuma capsules (3000 mg/day, three capsules) or placebo in identical capsules in a randomized, double blind mode for 24 weeks: 20 patients will receive curcumin, and 20 patients - placebo.

Participants will be assessed at baseline and after 4, 8, 12, 16 and 24 weeks of treatment. In a case of treatment discontinuation for 24-week of the trial, patients will be followed until end of study period.

Outcome variables will be evaluated by scoring the severity of symptoms (positive, negative, and etc.), and side effects. In addition, liver function tests and a blood cell count will be monitored at baseline and during the study.

For analyzing the results, within-subject pre- and post-treatment responses would be subject to statistical procedures to evaluate whether curcumin can ameliorate the persistent negative symptoms in schizophrenia.

Conditions

Chronic Schizophrenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

curcumin

curcumin 3 g/day for 6 months

Group Type: ACTIVE_COMPARATOR

Curcumin

Intervention Type: DRUG

3 g/day (3 capsules/day) for 6 months

placebo

Intervention Type: DRUG

3 g/day (3 capsules/day) for 6 months

placebo

curcumin 3 g/day for 6 months

Group Type: PLACEBO_COMPARATOR

Curcumin

Intervention Type: DRUG

3 g/day (3 capsules/day) for 6 months

placebo

Intervention Type: DRUG

3 g/day (3 capsules/day) for 6 months

Interventions

Curcumin

3 g/day (3 capsules/day) for 6 months

Intervention Type: DRUG

placebo

3 g/day (3 capsules/day) for 6 months

Intervention Type: DRUG

Other Intervention Names

placebo; regular antipsychotic medication; curcumin; regular antipsychotic medication

Eligibility Criteria

Inclusion Criteria

• Age 18-60 years, male or female
• DSM-IV criteria for schizophrenia.
• Ability and willingness to sign informed consent for participation in the study
• SANS (Scale of Negative Symptoms of Schizophrenia ) > 30 points
• Fixed antipsychotic dosages at least 3 months
• Steady mental state of patients at least 3 months

Exclusion Criteria

• Current substance use disorder except nicotine dependence
• Regular use of NSAID (non-steroidal anti-inflammatory drugs)
• Cancer history
• Untreated or severe hypertension
• Poorly controlled diabetes mellitus Type I or Type II
• Chronic liver & gallbladder diseases
• Recent GERD (Gastroesophageal Reflux Disorder)
• Neurological disorders: epilepsy, stroke
• Hamilton Depression Scale Hamilton Depression Rating Scale (HAM-D-17 item) > 24 points
• Patients with a known hypersensitivity to curcumin
• Pregnant women or a woman who intends to become pregnant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tirat Carmel Mental Health Center

OTHER_GOV

Sponsor Role: collaborator

Beersheva Mental Health Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Vladimir Lerner

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Vladimir Lerner, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Ben-Gurion University of the Negev

Locations

Beersheva Mental Health Center

Beersheva, , Israel

Tirat Carmel Mental Health Center

Tirat Carmel, , Israel

Countries

Israel

References

Miodownik C, Lerner V, Kudkaeva N, Lerner PP, Pashinian A, Bersudsky Y, Eliyahu R, Kreinin A, Bergman J. Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. Clin Neuropharmacol. 2019 Jul/Aug;42(4):117-122. doi: 10.1097/WNF.0000000000000344.

Reference Type: DERIVED

PMID: 31045590 (View on PubMed)

Other Identifiers

VLJB-14

Identifier Type: -

Identifier Source: org_study_id